PIRCHE
PIRCHE AG operates the TxPredictor platform, an AI-powered HLA epitope matching system that helps transplant centers predict donor-recipient immune compatibility, guide immunosuppression, and monitor post-transplant risk for solid organ and stem cell grafts.
- Company typePrivate
- Founded2014
- HeadquartersBerlin, Germany
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What PIRCHE does
PIRCHE AG is a Berlin-headquartered digital diagnostics company founded in 2014 that builds the TxPredictor platform, described as an Immune Intelligence Platform for transplantation medicine. The company's core technology predicts how a recipient's immune system will recognize and respond to donor organ HLA epitopes using proprietary T-cell epitope matching (PIRCHE-I for CD8+ and PIRCHE-II for CD4+ responses) and B-cell epitope matching via the Snow algorithm, both powered by AI neural networks trained on HLA binding motifs. The platform processes genetic typing data on a high-performance cloud infrastructure and integrates with major HLA laboratory IT systems, offering six functional modules (RAMP, Tmem, Outcomes Prediction, Donor Selection, HSCT Search Profile) that support donor selection, immunosuppression management, and post-transplant surveillance for solid organ and stem cell transplantation, as well as emerging use cases in cell therapy and immuno-oncology.
The company commercializes TxPredictor as a subscription SaaS product through three access tiers (Routine, Research, Demo) sold via enterprise field sales targeting transplant centers and HLA laboratories globally. Distribution is augmented by integration partnerships — notably with Werfen (MatchX API), Natera (companion prognostics combining PIRCHE scores with Prospera dd-cfDNA monitoring), and Mayo Clinic for clinical validation — alongside educational partnerships with AST, TTC, and GenDx. PIRCHE cites more than 1 million real-world transplant cases processed and 200+ peer-reviewed publications supporting clinical utility. The company is privately held as a German Aktiengesellschaft, maintains a US regional office in Walpole, Massachusetts, has a small leadership team, and is actively soliciting external investment.
PIRCHE firmographics
Firmographics- Name
- PIRCHE
- Legal name
- Pirche AG
- Website
- https://pirche.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PIRCHE AG operates the TxPredictor platform, an AI-powered HLA epitope matching system that helps transplant centers predict donor-recipient immune compatibility, guide immunosuppression, and monitor post-transplant risk for solid organ and stem cell grafts.
- Ownership category
- akta.pro rank
PIRCHE industry classification
Industry- Product category
- Transplant Immunology Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL)
Keywords
Where PIRCHE is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
PIRCHE business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- TxPredictor Platform Subscription: PIRCHE operates as a SaaS platform (TxPredictor) providing molecular HLA epitope matching services to transplant centers and HLA laboratories. The platform is offered through a cloud-based subscription model with different access levels including routine access, research access, and demo access.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Platform access tiers for different user needs |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
PIRCHE product offering
Product offeringCore offering
PIRCHE develops and sells the TxPredictor platform, a cloud-based Immune Intelligence Platform that uses AI-supported immunological simulations to predict how a recipient's immune system will recognize and respond to donor organ HLA epitopes. The platform combines T cell epitope matching (PIRCHE-I and PIRCHE-II) with B cell epitope matching (Snow algorithm) to quantify pre-transplant immunologic risk, support donor selection, guide immunosuppression, and enable personalized post-transplant surveillance for solid organ and stem cell transplant centers and HLA laboratories.
Product overview
PIRCHE offers a platform-plus-modules architecture centered on the TxPredictor platform, the world's first Immune Intelligence Platform. The platform uses AI neural networks to analyze genetic HLA typing data and predict immunogenicity scores for transplant compatibility assessment. The product portfolio includes six modules: RAMP (Risk and Acceptable Mismatch Profile) for donor selection and immunosuppression management, Tmem for T-cell memory response modeling, Outcomes Prediction for clinical risk assessment, Donor Selection for multi-donor comparison, and HSCT Search Profile for stem cell donor identification. The platform integrates predictive PIRCHE immunogenicity scores with real-time dd-cfDNA injury detection through companion prognostics partnerships, transforming transplant care from reactive damage control to proactive precision surveillance.
Differentiator
Problem solved
Functional benefit
Products and services
- TxPredictor The world's first Immune Intelligence Platform that merges genetic typing with AI-supported immunological simulations, enabling clinicians and HLA laboratories to make precise, personalized medical decisions for transplant patients. Runs on high-performance cloud infrastructure with real-time analysis, integration with major HLA vendors' software, absolute and relative immunologic risk quantification, and low turnaround time.
- RAMP (Risk and Acceptable Mismatch Profile) Module supporting informed donor selection, immunosuppression management, and post-transplant monitoring by predicting epitope mismatches at the locus level. Allows users to evaluate how individual mismatches contribute to overall PIRCHE-T2 and PIRCHE-B scores and match donor populations to patients.
- Tmem (T Memory) Module modeling T-cell memory responses that standard HLA testing cannot detect. Uses previous immunizer data to provide insight into potential post-transplant antibody risks by identifying HLA mismatches the immune system may have encountered before, distinguishing typical unacceptable mismatches from those associated with prior immune activation.
- Outcomes Prediction Module (OPM) Module providing transplant teams with comprehensive understanding of factors influencing transplant outcomes by incorporating key clinical variables such as patient age, race, prior transplants alongside HLA molecular matching data. Available through the Early Access Program.
- Donor Selection Module Tool supporting both solid organ and stem cell transplantation by allowing clinicians to compare multiple donors for a single patient using comprehensive immune profiling. Evaluates immunologic compatibility in real time with color-coded heatmaps highlighting which HLA mismatches most strongly contribute to total immunogenicity.
- HSCT Search Profile Module designed for hematopoietic stem cell transplant teams to identify low-epitope-mismatched HLA combinations even without access to a full stem cell donor registry. Estimates likelihood of finding a donor with a low PIRCHE score and presents data in combined table and chart view.
Quantifiable outcome
- Low PIRCHE score can help rule out development of harmful antibodies 94.2% of the time (Santos et al.)
- +2 more outcomes
Companies that use PIRCHE
Customer profileSegments2 records
Ideal customer profiles2 records
PIRCHE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature4 records
PIRCHE partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core and minor.
- Natera, Inc.flagshipStrategic collaboration to advance transplant medicine by combining pre-transplant immunological risk assessment using PIRCHE's TxPredictor platform with post-transplant molecular monitoring using Natera's Prospera dd-cfDNA test. The partnership integrates PIRCHE's risk-stratification with dd-cfDNA monitoring to provide comprehensive data-driven patient immune status analysis across the transplant journey. Joint offerings planned for launch at the 2026 American Transplant Congress in June.
- Werfen (formerly Immucor)coreMatchX API integration partnership providing customers with next-generation antibody analysis utilizing epitope scoring. Integrates PIRCHE's advanced epitope matching technology with Werfen's comprehensive suite of transfusion and transplantation diagnostic solutions.
- AST (American Society of Transplantation)minorPartnership for educational webinars and professional education in transplant immunology and epitope matching technology.
- TTC (The Transplantation Society)minorPartnership for educational content and professional development in transplantation medicine.
- Mayo CliniccoreMayo Clinic partnership for clinical validation and research collaboration in epitope matching for improved organ donor-recipient matching.
- GenDxminorCollaborative webinar partnership for PIRCHE epitope matching education in kidney transplantation case studies.
Scale indicators2 records
Recent moves6 records
Expansion highlights7 records
PIRCHE competitors and assessment
Company assessmentBroad incumbents
- Immucor (Werfen Transplant Diagnostics): Werfen's Transplant Diagnostics business (formerly Immucor/Lifecodes) provides HLA typing and antibody analysis products and the MatchX platform — a direct integration partner of PIRCHE and the closest broad incumbent competing in the same HLA lab workflow.
- Thermo Fisher Scientific (One Lambda): One Lambda, part of Thermo Fisher, is the dominant incumbent in HLA typing reagents and laboratory software for transplant diagnostics — offering overlapping functionality to PIRCHE within an established global installed base.
- CareDx: CareDx is a transplant-focused diagnostics company with AlloSure dd-cfDNA and other post-transplant monitoring solutions, making it both a strategic complement and the most credible broad incumbent in the transplant decision-support market adjacent to PIRCHE.
Emerging players
- Eurofins Transplant Genomics: Eurofins Transplant Genomics offers TruGraf blood-based graft monitoring for transplant patients — an emerging diagnostics player whose post-transplant monitoring focus overlaps with the PIRCHE companion-prognostics workflow.
- Natera: Natera's Prospera dd-cfDNA test is the post-transplant monitoring arm of the PIRCHE companion-prognostics partnership, making Natera a strategic ally whose own transplant roadmap directly intersects with PIRCHE's pre-transplant risk offering.
Direct peers
- Devyser: Devyser develops HLA and transplant-related genetic testing kits and software — a listed PIRCHE integration partner operating in the same HLA diagnostics space with comparable transplant-center customers.
- HistoTrac: HistoTrac provides HLA laboratory information management software used by transplant labs — listed alongside PIRCHE for custom HLA interface integrations, making it a direct peer and channel partner in the same HLA lab IT ecosystem.
- GenDx: GenDx provides HLA typing reagents and laboratory software (SBT, NGS, and analysis tools) used by transplant labs — directly overlapping with PIRCHE's HLA software footprint and listed as a PIRCHE integration and education partner.
Regional players
- Eurotransplant: Eurotransplant is the European organ allocation foundation referenced in PIRCHE research collaborations — a regional allocator whose HLA matching standards influence adoption of epitope-matching technologies like PIRCHE across European transplant centers.
Others
- Veloxis Pharmaceuticals: Veloxis is a transplant-focused immunosuppression specialty pharmaceutical company — adjacent rather than directly competing, but a relevant peer for the transplant ecosystem in which PIRCHE's risk-stratification outputs inform immunosuppression decisions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
PIRCHE social profiles
Digital presencePIRCHE financial estimates
Financial estimateRevenue estimate
Valuation estimate
PIRCHE leadership team
Management profileNumber of profiles
Profiles6 records
PIRCHE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PIRCHE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PIRCHE
What does PIRCHE do?
PIRCHE develops and sells the TxPredictor platform, a cloud-based Immune Intelligence Platform that uses AI-supported immunological simulations to predict how a recipient's immune system will recognize and respond to donor organ HLA epitopes. The platform combines T cell epitope matching (PIRCHE-I and PIRCHE-II) with B cell epitope matching (Snow algorithm) to quantify pre-transplant immunologic risk, support donor selection, guide immunosuppression, and enable personalized post-transplant surveillance for solid organ and stem cell transplant centers and HLA laboratories.
Is PIRCHE a public or private company?
PIRCHE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PIRCHE founded?
PIRCHE was founded in 2014. It employs 1 to 10 people.
Where is PIRCHE based?
PIRCHE is headquartered in Berlin, Germany, in the Europe region.
How does PIRCHE make money?
One revenue line is on record: txPredictor Platform Subscription.
Who are PIRCHE's main competitors?
Broad incumbents on record are Immucor (Werfen Transplant Diagnostics), Thermo Fisher Scientific (One Lambda) and CareDx. Emerging players are Eurofins Transplant Genomics and Natera. Direct peers are Devyser, HistoTrac and GenDx. Eurotransplant is listed as a regional player. Veloxis Pharmaceuticals is listed as an others.
Does PIRCHE have an API?
No public API is recorded for PIRCHE.
What industry is PIRCHE in?
PIRCHE's product category is Transplant Immunology Software. Its primary akta.pro industry code is HLACAMAL, Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery). Its NAICS code is 54151 and its SIC code is 7372.